RFG
AVIR icon

REAP Financial Group’s Atea Pharmaceuticals AVIR Stock Holding History

REAP Financial Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$538 Buy
+100
New +$459 ﹤0.01% 508

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

REAP Financial Group's AVIR Position: Q1 2026 in Review

REAP Financial Group opened a new position in Atea Pharmaceuticals (AVIR) in Q1 2026: 100 shares worth $538. The stake represents ﹤0.01% of the portfolio and ranks #508 among its holdings.

127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • REAP Financial Group held 100 shares of Atea Pharmaceuticals worth $538 as of Q1 2026.
  • Atea Pharmaceuticals was a new REAP Financial Group position in Q1 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of REAP Financial Group's portfolio in Q1 2026, its #508 holding.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on REAP Financial Group's 13F filing for Q1 2026, filed 11 May 2026.